Alex Howarth is an industry leading financial executive with a long record of success building finance, corporate development, legal, compliance, regulatory and supply chain functions within commercial-stage public and private biotech and specialty pharma companies. Over the course of his career, Mr. Howarth has completed more than 30 licensing and M&A transactions.
Most recently Mr. Howarth was Chief Financial Officer (CFO), Madrigal Pharmaceuticals, a public global biopharmaceutical company that developed and commercializes Rezdiffra, the first approved treatment for metabolic dysfunction-associated steatohepatitis (MASH), the leading cause of liver transplants in the United States. Mr. Howarth led the long-range strategic planning and implementation that supported the company’s transition to a commercial organization. Rezdiffra’s first full year sales totaled nearly $1 billion. During his tenure, Mr. Howarth secured $750 million through equity and debt financings to support the company’s growth.
Prior to joining Madrigal, Mr. Howarth served as Chief Operating Officer, Akcea Therapeutics, where he led the company’s sale in a transaction valued at $2 billion. Earlier roles include President and CFO at Lycera Corporation, CFO at moksha8, and a series of positions increasing in responsibility at Vitae Pharmaceuticals, GlaxoSmithKline (GSK), and KPMG.
Mr. Howarth is a Fellow Chartered Accountant and holds a BSc in Biochemistry, from the University of Bath in the United Kingdom.
